weight gain after glp 1 New study finds rapid gains are possible stopping GLP-1 drugs GLP-1 receptor agonists 'superior' for

Although clinical trials can provide powerful evidence to evaluate the efficacy of novel drugs, their ability to draw definitive conclusions about drug safety is limited due to the finite scope, restricted time frame, strict study entry criteria, and relatively small sample sizes

Recent observational studies have suggested associations between GLP-1 receptor agonist use in people with type 2 diabetes and reduced dementia risk compared to other diabetes medications

( 10.3390/biomedicines9070832) [DOI] [PMC free article] [PubMed] [Google Scholar] Timmers L, Henriques JPS, de Kleijn DPV, Devries JH, Kemperman H, Steendijk P, Verlaan CWJ, Kerver M, Piek JJ, Doevendans PA, et al

What Do Preclinical Efficacy Studies Indicate

These tests can help identify issues like thyroid problems, insulin resistance, or PCOS

However, the authors note that the certainty of evidence was low